Literature DB >> 6546839

Pharmacokinetic aspects of intrathecal morphine analgesia.

G Nordberg, T Hedner, T Mellstrand, B Dahlström.   

Abstract

Fifteen patients undergoing thoracotomy were given 0.25 or 0.50 mg morphine intrathecally (L2-L3 or L3-L4) for an analgetic and pharmacokinetic study. Administration of morphine at the end of the operation resulted in a highly variable duration of analgesia ranging from 1-20.5 and 1-40 h for the 0.25 and 0.50 mg groups, respectively. Calculation of cumulative consumption pattern of additional analgesics given im indicated a dose-related analgesia lasting around 12 h. Morphine concentrations in the CSF were high and dose dependent. Thus, at 1 h, CSF concentrations (means +/- SEM) were 4,228 +/- 361 ng/ml and 10,447 +/- 1,538 ng/ml for the 0.25 and 0.50-mg groups, respectively. The plasma concentrations generally were very low, i.e., under 1 ng/ml. For the 0.50 and 0.25 mg groups, the terminal elimination half-life in CSF was 175 +/- 9 min and 196 +/- 13 min, respectively: the volume of CSF distribution was 0.88 +/- 0.16 ml X kg-1 and 1.06 +/- 0.17 ml X kg-1, respectively: and the clearance from CSF was 2.81 +/- 0.41 microliter X kg-1 X min-1 and 3.41 +/- 0.55 microliter X kg-1 X min-1, respectively (means +/- SEM). The study indicates that the significant pharmacokinetic parameter related to the long duration of analgesia after intrathecal morphine administration probably is the high CSF concentrations found, since the rate of elimination from CSF is similar to what is reported for morphine in plasma. Furthermore, modulation of nociceptive input in the thoracic region also may be achieved by lumbar administration, but a slower onset should be anticipated.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6546839     DOI: 10.1097/00000542-198405000-00010

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  21 in total

Review 1.  Intrathecal drug administration. Present use and future trends.

Authors:  J S Kroin
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Neuraxial morphine and respiratory depression: finding the right balance.

Authors:  Pervez Sultan; Maria Cristina Gutierrez; Brendan Carvalho
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

3.  Spinal anaesthesia with meperidine as the sole agent.

Authors:  C E Famewo; M Naguib
Journal:  Can Anaesth Soc J       Date:  1985-09

4.  Intrathecal morphine for postoperative pain control following robot-assisted prostatectomy: a prospective randomized trial.

Authors:  Junyeol Bae; Hyun-Chang Kim; Deok Man Hong
Journal:  J Anesth       Date:  2017-05-05       Impact factor: 2.078

Review 5.  Spinal opioid analgesia. A critical update.

Authors:  L L Gustafsson; Z Wiesenfeld-Hallin
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

6.  The pharmacokinetics of intradural morphine in major abdominal surgery.

Authors:  T I Ionescu; R H Drost; J M Roelofs; E K Winckers; R H Taverne; A A van Maris; J M van Rossum
Journal:  Clin Pharmacokinet       Date:  1988-03       Impact factor: 6.447

7.  Pharmacokinetics of epidural morphine in man.

Authors:  G Nordberg; T Hedner; T Mellstrand; L Borg
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 8.  Newer methods of delivery of opiates for relief of pain.

Authors:  P J Slattery; R A Boas
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

9.  CSF and plasma pharmacokinetics of pethidine and norpethidine in man after epidural and intrathecal administration of pethidine.

Authors:  G Nordberg; V Hansdottir; U Bondesson; L O Boréus; T Mellstrand; T Hedner
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine.

Authors:  Ingolf Meineke; Stefan Freudenthaler; Ute Hofmann; Elke Schaeffeler; Gerd Mikus; Matthias Schwab; Hilmar W Prange; Christoph H Gleiter; J Brockmöller
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.